Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

NCT03278626 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped The study was stopped earlier than anticipated due to slow accrual

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Nivolimumab+Carboplatin/paclitaxel+Radiation

Sponsor

NYU Langone Health